Thanks for the color on HES. Any idea why they haven't issued new debt at these ridiculous interest rates that every other company seemingly has? They have over $5b outstanding in the range of 5.6-8.1% fixed rates - you'd think they could improve on that and replace some.
Opinions and comments may have been previously posted @BioDueDiligence, at www.biotechduediligence.com, or disseminated to Chimera Research Group subscribers.